Abstract
The use of pharmacologic agents to maintain remission following allogeneic hematopoietic cell transplantation (HCT) is a topic of increasing interest and exploration for patients with high-risk acute myeloid leukemia (AML). This review details published and ongoing studies focused on post-transplant pharmacologic maintenance for AML. While early phase studies have demonstrated the safety and tolerability of various maintenance approaches following HCT, the results of several ongoing randomized prospective studies will be required to determine the clinical efficacy needed to expand this approach from experimental to standard of care.
Keywords:
Clinical results; chemotherapeutic approaches; myeloid leukemias and dysplasias.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
DNA Methylation / drug effects
-
Hematopoietic Stem Cell Transplantation* / adverse effects
-
Hematopoietic Stem Cell Transplantation* / methods
-
Humans
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / pathology
-
Leukemia, Myeloid, Acute / therapy*
-
Maintenance Chemotherapy*
-
Molecular Targeted Therapy
-
Mutation
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Transplantation, Homologous
-
Treatment Outcome
-
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
-
fms-Like Tyrosine Kinase 3 / genetics
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3